Literature DB >> 8803661

Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome.

A G Awad1, L N Voruganti, R J Heslegrave, T P Hogan.   

Abstract

The concept of subjective response to neuroleptics in schizophrenia was reviewed with particular focus on scales for its measurement. The significance of recognizing such a phenomenon early on in the course of treatment has been illustrated by research data linking it to compliance, clinical improvement, quality of life, suicidal behaviour and comorbid drug abuse. Negative subjective response to neuroleptics has been identified as a strong predictor of compliance and outcome. Awareness of this subjective response in the management of the acute phase of the illness would require the physician to develop specific or additional approaches to the management of such dysphoric patients on neuroleptics at the time of discharge.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8803661     DOI: 10.1097/00004850-199605002-00009

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  12 in total

1.  Attitudes toward taking medication among outpatients with schizophrenia: cross-national comparison between Tokyo and Beijing.

Authors:  Naoaki Kuroda; Shiyou Sun; Chih-Kuang Lin; Nobuaki Morita; Hirotaka Kashiwase; Fude Yang; Yoji Nakatani
Journal:  Environ Health Prev Med       Date:  2008-08-12       Impact factor: 3.674

Review 2.  Patient compliance with drug therapy in schizophrenia. Economic and clinical issues.

Authors:  E Lindström; K Bingefors
Journal:  Pharmacoeconomics       Date:  2000-08       Impact factor: 4.981

Review 3.  Impact of atypical antipsychotics on quality of life in patients with schizophrenia.

Authors:  A George Awad; Lakshmi N P Voruganti
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 4.  Patients' subjective experiences of antipsychotics: clinical relevance.

Authors:  Jonathan S E Hellewell
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

5.  Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study).

Authors:  I García-Cabeza; J C Gómez; J A Sacristán; E Edgell; M González de Chavez
Journal:  BMC Psychiatry       Date:  2001-12-28       Impact factor: 3.630

6.  Behavioral and emotional adverse events of drugs frequently used in the treatment of bipolar disorders: clinical and theoretical implications.

Authors:  Alejandro Szmulewicz; Cecilia Samamé; Pablo Caravotta; Diego J Martino; Ana Igoa; Diego Hidalgo-Mazzei; Francesc Colom; Sergio A Strejilevich
Journal:  Int J Bipolar Disord       Date:  2016-02-16

7.  Attitudes toward medication and the clinical variables in schizophrenia: Structural equation models.

Authors:  Alessandro Rossi; Roberta Pacifico; Paolo Stratta
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

8.  Preliminary data concerning the reliability and psychometric properties of the Greek translation of the 20-item Subjective Well-Being Under Neuroleptic Treatment Scale (SWN-20).

Authors:  Melina Siamouli; Katerina Moutou; Eleonora Pantoula; Stamatia Magiria; Irini Chatzivasileiou; Konstantinos Arapidis; Achileas Chatzivasileiou; Simeon Deres; Konstantinos N Fountoulakis
Journal:  Ann Gen Psychiatry       Date:  2009-01-21       Impact factor: 3.455

9.  The Self-Perception and Relationships Tool (S-PRT): a novel approach to the measurement of subjective health-related quality of life.

Authors:  Mark J Atkinson; Paul M Wishart; Bushra I Wasil; John W Robinson
Journal:  Health Qual Life Outcomes       Date:  2004-07-16       Impact factor: 3.186

10.  Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.

Authors:  George Awad; Mariam Hassan; Antony Loebel; Jay Hsu; Andrei Pikalov; Krithika Rajagopalan
Journal:  BMC Psychiatry       Date:  2014-02-23       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.